T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models of AML, ovarian, pancreatic cancers
April 16, 2018
| By Rachel Tompa / Fred Hutch News Service
In an effort to improve the efficacy of immunotherapy for solid tumors, Fred Hutch researchers have engineered a new type of protein that can rewire a 'kill switch' to stimulate T cells' activity instead.
An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.
New research writes latest chapter in one drug's story
June 27, 2017
| by Susan Keown / Fred Hutch News Service
The leukemia drug gemtuzumab ozogamicin (Mylotarg) was pulled from the market seven years after initial approval. Now, new evidence may be bringing it back to life to treat a specific group of patients.
Among 'a lot of brilliant guys,' the leukemia clinician-researcher stood out for his science — and much more
June 2, 2017
| By Mary Engel / Fred Hutch News Service
Dr. Steven J. Collins' research into the molecular genetics of myeloid leukemias changed the way scientists thought about cancer cells and led to the development of one of the earliest targeted therapies.
Dr. Glenda Gray among Time magazine’s ‘100 most influential’; Fred Hutch license plates coming soon; UW establishes Dr. Oliver W. Press Distinguished MSTP Alumnus Award; and Dr. Vivian Oehler receives ASH Bridge Grant for leukemia research.